Introduction to Versus Adalimumab
Sentence Examples
Discover more insights into Versus Adalimumab
Keywords frequently search together with Versus Adalimumab
Narrow sentence examples with built-in keyword filters
Versus Adalimumab sentence examples within Abatacept Versus Adalimumab
The objective of this study was to describe the efficacy of subcutaneous abatacept versus adalimumab over 2 years in patients with seropositive, erosive early RA in the AMPLE study.
The objective of this study was to describe the efficacy of subcutaneous abatacept versus adalimumab over 2 years in patients with seropositive, erosive early RA in the AMPLE study.
Full Text
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Full Text
Versus Adalimumab sentence examples within Infliximab Versus Adalimumab
Las Cs subterapéuticas/indetectables fueron significativamente (p≤0,004) más frecuentes en pacientes tratados con infliximab versus adalimumab (64,1% vs.
Las Cs subterapéuticas/indetectables fueron significativamente (p≤0,004) más frecuentes en pacientes tratados con infliximab versus adalimumab (64,1% vs.
Full Text
Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion.
Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion.
Full Text
Versus Adalimumab sentence examples within Upadacitinib Versus Adalimumab
The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1.
The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1.
Full Text
Results Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation).
Results Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation).
Full Text
Versus Adalimumab sentence examples within Superiority Versus Adalimumab
In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain.
In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain.
Full Text
Sarilumab 200 mg showed superiority versus adalimumab monotherapy on all efficacy outcomes and versus tofacitinib monotherapy on ACR20.
Sarilumab 200 mg showed superiority versus adalimumab monotherapy on all efficacy outcomes and versus tofacitinib monotherapy on ACR20.
Full Text
Versus Adalimumab sentence examples within Baricitinib Versus Adalimumab
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment withLaura Cometi: None declared, Cosimo Bruni Speakers bureau: Actelion, Consultant of: Eli Lilly, Grant/research support from: Fondazione Italiana Ricerca sull’Artrite (FIRA), Gruppo Italiano lotta alla Sclerodermia (GILS), New Horizon Fellowship, European Scleroderma Trials and Research (EUSTAR) group, Foundation for Research in Rheumatology (FOREUM).
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment withLaura Cometi: None declared, Cosimo Bruni Speakers bureau: Actelion, Consultant of: Eli Lilly, Grant/research support from: Fondazione Italiana Ricerca sull’Artrite (FIRA), Gruppo Italiano lotta alla Sclerodermia (GILS), New Horizon Fellowship, European Scleroderma Trials and Research (EUSTAR) group, Foundation for Research in Rheumatology (FOREUM).
Full Text
Objectives: To evaluate the cost-effectiveness of baricitinib versus adalimumab for the treatment of moderately-to-severely active RA in the Spanish setting.
Objectives: To evaluate the cost-effectiveness of baricitinib versus adalimumab for the treatment of moderately-to-severely active RA in the Spanish setting.
Full Text
Versus Adalimumab sentence examples within Vedolizumab Versus Adalimumab
BACKGROUND AND AIMS
VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab.
BACKGROUND AND AIMS
VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab.
Full Text
A propensity score matched cohort study of vedolizumab versus anti-TNF therapy in ulcerative colitis observed a point estimate for comparative effectiveness that was nearly identical to that achieved by a head-to-head phase 3 double-blind randomized control trial of vedolizumab versus adalimumab.
A propensity score matched cohort study of vedolizumab versus anti-TNF therapy in ulcerative colitis observed a point estimate for comparative effectiveness that was nearly identical to that achieved by a head-to-head phase 3 double-blind randomized control trial of vedolizumab versus adalimumab.
Full Text
Versus Adalimumab sentence examples within versus adalimumab comparison
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Full Text
Abatacept versus adaliMumab comParison in bioLogic-naivE RA subjects with background MTX (AMPLE) was the first head-to-head randomised controlled trial to evaluate the efficacy of abatacept (ABA) and adalimumab.
Abatacept versus adaliMumab comParison in bioLogic-naivE RA subjects with background MTX (AMPLE) was the first head-to-head randomised controlled trial to evaluate the efficacy of abatacept (ABA) and adalimumab.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40278-021-97468-3
Similarly, there was no increased risk of MACE within 91 days after exposure to ustekinumab versus adalimumab (HR 0.
Similarly, there was no increased risk of MACE within 91 days after exposure to ustekinumab versus adalimumab (HR 0.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40278-021-95342-0
When results were restricted to those in patients receiving JAK inhibitors associated with conventional synthetic DMARDs, there were significant differences for placebo versus adalimumab, methotrexate, Pf-06650833, baricitinib and upadacitinib.
When results were restricted to those in patients receiving JAK inhibitors associated with conventional synthetic DMARDs, there were significant differences for placebo versus adalimumab, methotrexate, Pf-06650833, baricitinib and upadacitinib.
Full Text
More Versus Adalimumab sentence examples
10.1097/MPG.0000000000003098
Routine use of co-immunosuppression was significantly higher with infliximab (IFX) versus adalimumab (ADL) ([61/70, 87.
Routine use of co-immunosuppression was significantly higher with infliximab (IFX) versus adalimumab (ADL) ([61/70, 87.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40744-021-00361-5
Machine learning was used to identify a rule to predict the response to sarilumab and discriminate between responses to sarilumab versus adalimumab, with a focus on clinically feasible blood biomarkers.
Machine learning was used to identify a rule to predict the response to sarilumab and discriminate between responses to sarilumab versus adalimumab, with a focus on clinically feasible blood biomarkers.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40744-021-00379-9
The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1.
The aim of this work is to assess the effect of upadacitinib versus adalimumab and placebo on patient-reported outcomes (PROs) in psoriatic arthritis (PsA) patients with inadequate responses to ≥ 1 non-biologic disease-modifying anti-rheumatic drugs (non-bDMARD-IR) in SELECT PsA-1.
Full Text
More Versus Adalimumab sentence examples
10.1136/ANNRHEUMDIS-2021-EULAR.1343
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment withLaura Cometi: None declared, Cosimo Bruni Speakers bureau: Actelion, Consultant of: Eli Lilly, Grant/research support from: Fondazione Italiana Ricerca sull’Artrite (FIRA), Gruppo Italiano lotta alla Sclerodermia (GILS), New Horizon Fellowship, European Scleroderma Trials and Research (EUSTAR) group, Foundation for Research in Rheumatology (FOREUM).
Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment withLaura Cometi: None declared, Cosimo Bruni Speakers bureau: Actelion, Consultant of: Eli Lilly, Grant/research support from: Fondazione Italiana Ricerca sull’Artrite (FIRA), Gruppo Italiano lotta alla Sclerodermia (GILS), New Horizon Fellowship, European Scleroderma Trials and Research (EUSTAR) group, Foundation for Research in Rheumatology (FOREUM).
Full Text
More Versus Adalimumab sentence examples
10.1155/2021/9940391
We present a case of Sweet syndrome secondary to ulcerative colitis flare versus adalimumab re-induction.
We present a case of Sweet syndrome secondary to ulcerative colitis flare versus adalimumab re-induction.
Full Text
More Versus Adalimumab sentence examples
10.1093/RHEUMATOLOGY/KEAB247.184
The primary endpoint was superiority of secukinumab versus adalimumab on ACR20 response at Week 52.
The primary endpoint was superiority of secukinumab versus adalimumab on ACR20 response at Week 52.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40265-021-01476-3
In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain.
In the head-to-head EXCEED trial, secukinumab did not quite attain statistical significance for superiority versus adalimumab in the joint domain.
Full Text
More Versus Adalimumab sentence examples
10.4321/S1699-714X20210001000012
Las Cs subterapéuticas/indetectables fueron significativamente (p≤0,004) más frecuentes en pacientes tratados con infliximab versus adalimumab (64,1% vs.
Las Cs subterapéuticas/indetectables fueron significativamente (p≤0,004) más frecuentes en pacientes tratados con infliximab versus adalimumab (64,1% vs.
Full Text
More Versus Adalimumab sentence examples
10.1007/s00393-021-01013-3
We performed a Bayesian network meta-analysis combining direct and indirect evidence from randomized controlled trials (RCTs) examining efficacy and safety of adalimumab biosimilars versus adalimumab in patients with active RA despite MTX therapy.
We performed a Bayesian network meta-analysis combining direct and indirect evidence from randomized controlled trials (RCTs) examining efficacy and safety of adalimumab biosimilars versus adalimumab in patients with active RA despite MTX therapy.
Full Text
More Versus Adalimumab sentence examples
10.1053/j.gastro.2021.06.015
BACKGROUND AND AIMS
VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab.
BACKGROUND AND AIMS
VARSITY showed superior clinical remission and endoscopic improvement in ulcerative colitis with vedolizumab versus adalimumab.
Full Text
More Versus Adalimumab sentence examples
10.1186/s13075-021-02607-7
Conclusions In MTX-IR patients with early, autoantibody-positive RA, abatacept resulted in numerically higher efficacy responses versus adalimumab after 24 weeks, with more pronounced treatment differences in SE-positive patients.
Conclusions In MTX-IR patients with early, autoantibody-positive RA, abatacept resulted in numerically higher efficacy responses versus adalimumab after 24 weeks, with more pronounced treatment differences in SE-positive patients.
Full Text
More Versus Adalimumab sentence examples
10.1007/s00431-021-04077-0
The only predictor associated with any complication was infliximab (versus adalimumab) therapy (hazard ratio [HR]: 2.
The only predictor associated with any complication was infliximab (versus adalimumab) therapy (hazard ratio [HR]: 2.
Full Text
More Versus Adalimumab sentence examples
10.1111/jgh.15451
A propensity score matched cohort study of vedolizumab versus anti-TNF therapy in ulcerative colitis observed a point estimate for comparative effectiveness that was nearly identical to that achieved by a head-to-head phase 3 double-blind randomized control trial of vedolizumab versus adalimumab.
A propensity score matched cohort study of vedolizumab versus anti-TNF therapy in ulcerative colitis observed a point estimate for comparative effectiveness that was nearly identical to that achieved by a head-to-head phase 3 double-blind randomized control trial of vedolizumab versus adalimumab.
Full Text
More Versus Adalimumab sentence examples
10.1093/ECCO-JCC/JJAB076.551
The VARSITY trial, the first head-to-head study comparing the efficacy and safety of biologics in patients with moderately to severely active ulcerative colitis (UC), demonstrated superior clinical remission with vedolizumab (VDZ) versus adalimumab (ADA) at week 52.
The VARSITY trial, the first head-to-head study comparing the efficacy and safety of biologics in patients with moderately to severely active ulcerative colitis (UC), demonstrated superior clinical remission with vedolizumab (VDZ) versus adalimumab (ADA) at week 52.
Full Text
More Versus Adalimumab sentence examples
10.1007/s40744-019-00174-7
The objective of this study was to describe the efficacy of subcutaneous abatacept versus adalimumab over 2 years in patients with seropositive, erosive early RA in the AMPLE study.
The objective of this study was to describe the efficacy of subcutaneous abatacept versus adalimumab over 2 years in patients with seropositive, erosive early RA in the AMPLE study.
Full Text
More Versus Adalimumab sentence examples
10.1136/annrheumdis-2019-215764
Results Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation).
Results Consistent with responses through week 26, from weeks 26 to 48, responses by randomised group including low disease activity, clinical remission and improvements in pain and function remained superior for upadacitinib versus adalimumab; radiographical progression remained lower for upadacitinib versus placebo (linear extrapolation).
Full Text
More Versus Adalimumab sentence examples
10.3899/jrheum.181061
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Relationship between disease measures defining remission in the AMPLE trial (Abatacept Versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate).
Full Text
More Versus Adalimumab sentence examples
10.1136/annrheumdis-2019-eular.1457
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Adalimumab versus adalimumab and methotrexate for the treatment of juvenile idiopathic arthritis: long-term data from the German BIKER registry.
Full Text
More Versus Adalimumab sentence examples
10.1177/1756284819874202
Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion.
Randomization stratifies patients by the type of inflammatory bowel disease and drug (infliximab versus adalimumab) at study inclusion.
Full Text
More Versus Adalimumab sentence examples
10.1007/s12325-019-00912-x
Sarilumab 200 mg showed superiority versus adalimumab monotherapy on all efficacy outcomes and versus tofacitinib monotherapy on ACR20.
Sarilumab 200 mg showed superiority versus adalimumab monotherapy on all efficacy outcomes and versus tofacitinib monotherapy on ACR20.
Full Text
More Versus Adalimumab sentence examples
10.1016/j.jaad.2019.05.080
95) and phototherapy versus adalimumab (OR:4.
95) and phototherapy versus adalimumab (OR:4.
Full Text
More Versus Adalimumab sentence examples
10.2147/CEOR.S201621
Objectives: To evaluate the cost-effectiveness of baricitinib versus adalimumab for the treatment of moderately-to-severely active RA in the Spanish setting.
Objectives: To evaluate the cost-effectiveness of baricitinib versus adalimumab for the treatment of moderately-to-severely active RA in the Spanish setting.
Full Text
More Versus Adalimumab sentence examples
10.3899/jrheum.180904
Two phase III, randomized, controlled trials of sarilumab in patients with active, longstanding RA were analyzed: (1) sarilumab 150 mg and 200 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARD) versus placebo + csDMARD [TARGET (NCT01709578)]; and (2) sarilumab 200 mg versus adalimumab (ADA) 40 mg monotherapy [MONARCH (NCT02332590)].
Two phase III, randomized, controlled trials of sarilumab in patients with active, longstanding RA were analyzed: (1) sarilumab 150 mg and 200 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs (+csDMARD) versus placebo + csDMARD [TARGET (NCT01709578)]; and (2) sarilumab 200 mg versus adalimumab (ADA) 40 mg monotherapy [MONARCH (NCT02332590)].
Full Text
More Versus Adalimumab sentence examples
10.1080/09546634.2019.1628172
Mean changes (improvements) were greater in guselkumab-treated versus adalimumab-treated patients in the work limitations domains of Physical Demands (−6.
Mean changes (improvements) were greater in guselkumab-treated versus adalimumab-treated patients in the work limitations domains of Physical Demands (−6.
Full Text
More Versus Adalimumab sentence examples
10.1093/ibd/izy322
METHODS
We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for withdrawal in UC patients.
METHODS
We aimed to compare the treatment persistence rates of infliximab versus adalimumab as first- and second-line tumor necrosis factor antagonists (anti-TNF), to identify factors potentially associated with persistence, and to evaluate reasons for withdrawal in UC patients.
Full Text
More Versus Adalimumab sentence examples
10.1136/annrheumdis-2019-eular.1447
Abatacept versus adaliMumab comParison in bioLogic-naivE RA subjects with background MTX (AMPLE) was the first head-to-head randomised controlled trial to evaluate the efficacy of abatacept (ABA) and adalimumab.
Abatacept versus adaliMumab comParison in bioLogic-naivE RA subjects with background MTX (AMPLE) was the first head-to-head randomised controlled trial to evaluate the efficacy of abatacept (ABA) and adalimumab.
Full Text
More Versus Adalimumab sentence examples
10.1007/s00296-019-04352-2
The AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE RA subjects with background methotrexate) trial was a head-to-head, randomized study comparing abatacept with adalimumab.
The AMPLE (Abatacept versus adaliMumab comParison in bioLogic-naïvE RA subjects with background methotrexate) trial was a head-to-head, randomized study comparing abatacept with adalimumab.
Full Text
More Versus Adalimumab sentence examples
10.1080/09546634.2019.1679336
Treatment differences for guselkumab versus adalimumab were 25.
Treatment differences for guselkumab versus adalimumab were 25.
Full Text
Learn more from Versus Adalimumab
Keywords related to Versus
Versus Ablation
Versus Stochastic
Versus Contrast
Versus Microbial
Versus Generalized
Versus Slow
Versus Outpatient
Versus Interrupted
Versus Switching
Versus Nasal
Versus Metachronous
Versus Normocapnia
Versus Pneumatic
Versus Colonic
Versus Theoretical
Versus Consumer
Versus Inhaled
Versus Total
Versus Unilateral
Versus Bony
Versus Physicians
Versus Non Locking
Versus Autologous
Versus Splenectomy
Versus Age
Versus Insulin
Versus Punishment
Versus Stable
Versus Monopolar
Versus Composition
Versus Nuclear
Versus Stem
Versus Randomly
Versus Cooperative
Versus Vertebral
Versus Gene
Versus Gemcitabine
Versus Auditory
Versus Reconstruction
Versus Thoracoscopic
Versus Zoledronic
Versus Level
Versus Recent
Versus Acrylic
Versus Component
Versus Septic
Versus Inverse
Versus Small
Versus Abiotic
Versus Magnetic
Explore More
Keywords related to Adalimumab
Versus Adalimumab
Encyclopedia